Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge

Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge

Despite the lightning-fast advances in the management of SARS-CoV after 2 years of pandemic, COVID-19 continues to pose a challenge for fragile patients, who could benefit from early administration of monoclonal antibodies (mAbs) to reduce the risk of severe disease progression. We conducted a prosp...

Full description

Bibliographic Details
Main Authors: Riccardo Scotto, Antonio Riccardo Buonomo, Giulia Zumbo, Antonio Di Fusco, Nunzia Esposito, Isabella Di Filippo, Mariano Nobile, Biagio Pinchera, Nicola Schiano Moriello, Riccardo Villari, Ivan Gentile, Federico II COVID Team
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Vaccines
Subjects:
SARS-CoV-2
monoclonal antibodies
COVID-19
early treatment
real-life
chronic kidney disease
Online Access:https://www.mdpi.com/2076-393X/10/11/1895

Internet

https://www.mdpi.com/2076-393X/10/11/1895

Similar Items